首頁 > 市場調查報告書 > 製藥

骨疾病

市場調查報告書

商品編碼

1622333

骨關節炎治療市場規模、佔有率、成長分析、按解剖學、按藥物類型、按治療類型、按分銷管道、按地區 - 行業預測，2025-2032 年

Osteoarthritis Treatment Market Size, Share, Growth Analysis, By Anatomy, By Drug Type (Analgesics, Nonsteroidal Anti-Inflammatory Drugs ), By Treatment Type, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: 2024年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023年骨關節炎治療市場規模為87.1億美元，從2024年的94.5億美元成長到2032年的181.5億美元，預測期（2025-2032）預計複合年成長率為8.50%。

全球骨關節炎治療市場正在強勁成長，這主要是由於骨關節炎盛行率上升和人口老化。隨著預期壽命的延長，越來越多的老年人受到骨關節炎的影響，這增加了對有效管理策略的需求。醫療保健的進步刺激了對旨在減輕症狀和改善患者生活品質的創新治療解決方案的需求。此外，人們對治療方案和早期療育重要性的認知不斷提高也有助於市場擴張。醫療保健提供者正在積極對患者進行有關骨關節炎及其危險因素的教育，以實現早期診斷和及時治療。這種日益成長的意識正在推動對骨關節炎治療產品的需求，並進一步推動市場趨勢。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲

競爭資訊

前5名企業對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分類的佔有率分析
- 收益與前一年同期比較（2022-2024）

主要企業簡介

Sanofi（France）
Pfizer Inc.（USA）
Novartis AG（Switzerland）
Johnson & Johnson（USA）
GlaxoSmithKline plc（UK）
AbbVie Inc.（USA）
Eli Lilly and Company（USA）
Bayer AG（Germany）
Merck & Co., Inc.（USA）
Bristol Myers Squibb（USA）
AstraZeneca plc（UK）
Amgen Inc.（USA）
Haleon plc（UK）
Seikagaku Corporation（Japan）
Ono Pharmaceutical Co., Ltd.（Japan）
Assertio Holdings, Inc.（USA）
Zimmer Biomet Holdings, Inc.（USA）
Ferring Pharmaceuticals（Switzerland）
Genascence Corporation（USA）

結論和建議

簡介目錄

Product Code: SQMIG35A2305

Osteoarthritis Treatment Market size was valued at USD 8.71 Billion in 2023 and is poised to grow from USD 9.45 Billion in 2024 to USD 18.15 Billion by 2032, growing at a CAGR of 8.50% during the forecast period (2025-2032).

The global osteoarthritis treatment market is experiencing robust growth, primarily fueled by the rising incidence of osteoarthritis and an aging demographic. As life expectancy improves, more elderly individuals are becoming susceptible to this condition, thereby escalating the demand for effective management strategies. Advancements in healthcare have catalyzed the need for innovative treatment solutions aimed at alleviating symptoms and enhancing patient quality of life. Additionally, heightened awareness surrounding treatment options and the significance of early intervention are contributing to this market expansion. Healthcare providers are proactively educating patients about osteoarthritis and its risk factors, leading to earlier diagnosis and prompt treatment. This increasing awareness is driving the demand for osteoarthritis treatment products, further propelling market dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Osteoarthritis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Osteoarthritis Treatment Market Segmental Analysis

Global Osteoarthritis Treatment Market is segmented by anatomy, drug type, treatment type, distribution channel and region. Based on anatomy, the market is segmented into knee osteoarthritis, hip osteoarthritis, hand osteoarthritis and small joint osteoarthritis. Based on drug type, the market is segmented into analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, visco supplementation agents and others. Based on treatment type, the market is segmented into medication, surgery and therapy. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Osteoarthritis Treatment Market

The escalating prevalence of obesity worldwide plays a crucial role in the rising rates of osteoarthritis, thereby significantly influencing the osteoarthritis treatment market. As more individuals grapple with obesity, the incidence of osteoarthritis also climbs, prompting a heightened demand for effective treatment solutions. This trend is particularly evident as obese patients typically necessitate multifaceted strategies to manage their osteoarthritis symptoms. Consequently, the link between increasing obesity rates and the growing need for osteoarthritis treatments creates a compelling driver for market expansion, highlighting the urgent need for healthcare providers to offer targeted therapies and interventions to this affected population.

Restraints in the Osteoarthritis Treatment Market

One of the primary obstacles facing the osteoarthritis treatment market is the scarcity of disease-modifying therapies. Despite progress in research and treatment options, there is still an evident shortfall in effective therapies that can halt or alter the progression of osteoarthritis. This deficiency not only complicates the comprehensive management of the disease but also adversely affects the overall treatment success and quality of life for patients. Consequently, the lack of such innovative therapeutic approaches serves as a significant constraint, limiting potential advancements in the care and rehabilitation of individuals suffering from this debilitating condition.

Market Trends of the Osteoarthritis Treatment Market

The global Osteoarthritis Treatment market is witnessing a significant trend towards personalized and multimodal treatment strategies, reflecting a deeper understanding of the disease's complexity and varied patient responses. As the elderly population continues to grow, healthcare providers are moving away from traditional methods focused solely on pain management with NSAIDs and analgesics. Instead, they are increasingly incorporating physical therapy, lifestyle modifications, and innovative therapies such as biologics and regenerative medicine to create tailored treatment plans. This shift not only aims to alleviate symptoms but also to improve overall joint function and quality of life, positioning these personalized approaches at the forefront of osteoarthritis care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Patent Analysis

Global Osteoarthritis Treatment Market Size by Anatomy & CAGR (2025-2032)

Market Overview
Knee Osteoarthritis
Hip Osteoarthritis
Hand Osteoarthritis
Small Joint Osteoarthritis

Global Osteoarthritis Treatment Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Analgesics
- Acetaminophen
- Opioids
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Ibuprofen
- Naproxen
Corticosteroids
- Oral Corticosteroids
- Injectable Corticosteroids
Visco Supplementation Agents
- Hyaluronic Acid
Others
- Disease-Modifying Osteoarthritis Drugs (DMOADs)

Global Osteoarthritis Treatment Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Medication
Surgery
- Joint Replacement
- Arthroscopy
- Osteotomy
Therapy
- Physical Therapy
- Occupational Therapy

Global Osteoarthritis Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Osteoarthritis Treatment Market Size & CAGR (2025-2032)

North America (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- US
- Canada
Europe (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Anatomy, Drug Type, Treatment Type, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Haleon plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seikagaku Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ono Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Assertio Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zimmer Biomet Holdings, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring Pharmaceuticals (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genascence Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments